BR112017006232A2 - processos e intermediários na preparação de antagonistas de c5ar - Google Patents

processos e intermediários na preparação de antagonistas de c5ar

Info

Publication number
BR112017006232A2
BR112017006232A2 BR112017006232A BR112017006232A BR112017006232A2 BR 112017006232 A2 BR112017006232 A2 BR 112017006232A2 BR 112017006232 A BR112017006232 A BR 112017006232A BR 112017006232 A BR112017006232 A BR 112017006232A BR 112017006232 A2 BR112017006232 A2 BR 112017006232A2
Authority
BR
Brazil
Prior art keywords
intermediates
preparation
processes
c5ar antagonists
c5ar
Prior art date
Application number
BR112017006232A
Other languages
English (en)
Other versions
BR112017006232B1 (pt
Inventor
Krasinski Antoni
Tanaka Hiroko
Kalisiak Jaroslaw
Powers Jay
Zhang Penglie
Fan Pingchen
Lui Rebecca
Punna Sreenivas
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of BR112017006232A2 publication Critical patent/BR112017006232A2/pt
Publication of BR112017006232B1 publication Critical patent/BR112017006232B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

são fornecidos métodos e intermediários para a preparação de compostos antagonistas de c5ar selecionados.
BR112017006232-1A 2014-09-29 2015-09-28 Processos e intermediários na preparação de antagonistas de c5ar BR112017006232B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462057107P 2014-09-29 2014-09-29
US62/057,107 2014-09-29
PCT/US2015/052697 WO2016053890A1 (en) 2014-09-29 2015-09-28 PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS

Publications (2)

Publication Number Publication Date
BR112017006232A2 true BR112017006232A2 (pt) 2017-12-12
BR112017006232B1 BR112017006232B1 (pt) 2022-10-11

Family

ID=55583729

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006232-1A BR112017006232B1 (pt) 2014-09-29 2015-09-28 Processos e intermediários na preparação de antagonistas de c5ar

Country Status (19)

Country Link
US (5) US9745268B2 (pt)
EP (2) EP3682879B1 (pt)
JP (1) JP6898229B6 (pt)
KR (2) KR20230149873A (pt)
CN (2) CN113121415A (pt)
AU (2) AU2015324111B2 (pt)
BR (1) BR112017006232B1 (pt)
CA (2) CA3220371A1 (pt)
DK (1) DK3200791T3 (pt)
ES (2) ES2802428T3 (pt)
IL (1) IL251061B (pt)
MA (1) MA52308A (pt)
MX (2) MX368492B (pt)
NZ (2) NZ767823A (pt)
PL (1) PL3200791T3 (pt)
PT (1) PT3200791T (pt)
RU (1) RU2712233C2 (pt)
SG (1) SG11201702185UA (pt)
WO (1) WO2016053890A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172338A1 (en) 2008-12-22 2011-07-28 Chemocentryx Inc C5ar antagonists
US9126939B2 (en) * 2010-06-24 2015-09-08 Pingchen Fan C5AR antagonists
MA52308A (fr) * 2014-09-29 2021-02-24 Chemocentryx Inc Procédés et intermédiaires pour la préparation d'antagonistes c5ar
MX2022006069A (es) 2016-01-14 2023-01-12 Chemocentryx Inc Metodo para tratar glomerulopatia c3.
JP2021501175A (ja) 2017-10-30 2021-01-14 ケモセントリックス，インコーポレイティド 免疫調節剤としての重水素化化合物
WO2019236820A1 (en) 2018-06-07 2019-12-12 Chemocentryx, Inc. Dosing and effect of c5a antagonist with anca-associated vasculitis
IL283450B1 (en) 2018-11-30 2024-02-01 Chemocentryx Inc Solid solution capsule formulations containing (3S,2R)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl) Piperidine-3-carboxamide, methods for their preparation and their medical uses
KR102207333B1 (ko) * 2019-09-09 2021-01-27 성균관대학교산학협력단 4중 연속 고리 화합물의 신규한 제조방법
CN114641289A (zh) * 2019-11-08 2022-06-17 凯莫森特里克斯股份有限公司 补体成分C5a受体的游离碱晶型
TW202128623A (zh) 2019-11-08 2021-08-01 美商卡默森屈有限公司 補體成分Ｃ５ａ受體之鹽形式
WO2021092286A1 (en) 2019-11-08 2021-05-14 Chemocentryx, Inc. Amorphous form of a complement component c5a receptor
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途
WO2022263263A1 (en) 2021-06-16 2022-12-22 Sandoz Ag Crystalline form of avacopan
EP4137133A1 (en) 2021-08-19 2023-02-22 Sandoz AG Crystalline form of avacopan
CN113957106B (zh) * 2021-11-03 2024-04-19 暨明医药科技（苏州）有限公司 一种Avacopan及其中间体的制备方法
CN114262291B (zh) * 2022-01-04 2023-05-19 重庆医科大学 一种阿伐可泮的合成方法
WO2023158722A2 (en) 2022-02-16 2023-08-24 Teva Pharmaceuticals International Gmbh Processes for preparation of avacopan and intermediates thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
CN1261098C (zh) 1998-08-28 2006-06-28 西奥斯股份有限公司 p38－α激酶的抑制剂
RU2197288C2 (ru) 1999-08-03 2003-01-27 Тверская медицинская академия Способ лечения больных хроническим гломерулонефритом
AU2001259511A1 (en) 2000-05-05 2001-11-20 Smith Kline Beecham Corporation Novel anti-infectives
ES2353077T3 (es) 2000-08-10 2011-02-25 Mitsubishi Tanabe Pharma Corporation Derivados de urea con sustitución en posición 3 y uso medicinal de los mismos.
US7855297B2 (en) 2000-09-14 2010-12-21 Mitsubishi Tanabe Pharma Corporation Amide derivatives and medicinal use thereof
YU23503A (sh) 2000-09-29 2006-03-03 Neurogen Corporation Mali molekuli kao modulatori receptora c5a visokog afiniteta
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
DE10231783A1 (de) 2001-07-19 2003-03-20 Luk Lamellen & Kupplungsbau System zum Ansteuern einer Komponente eines Getriebes eines Fahrzeuges
CN100391537C (zh) 2001-08-17 2008-06-04 建南德克公司 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
TWI265164B (en) 2001-09-21 2006-11-01 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
CA2479930A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
AU2003225971A1 (en) 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
AU2003220553A1 (en) 2002-03-29 2003-10-20 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2004014905A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
FR2846654A1 (fr) 2002-11-05 2004-05-07 Servier Lab Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7455837B2 (en) 2002-11-05 2008-11-25 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
CA2504941C (en) 2002-11-08 2012-06-26 Neurogen Corporation 3-substituted-6-aryl pyridines
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
CA2528652A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
NZ551603A (en) 2004-06-24 2010-11-26 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
NZ561613A (en) 2005-02-18 2010-12-24 Astrazeneca Ab Antibacterial piperidine derivatives
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
JP5374157B2 (ja) 2005-11-24 2013-12-25 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ （ｒ）−アリールアルキルアミノ誘導体類と、それらを含有する薬剤組成物
EP4316465A3 (en) 2006-03-15 2024-04-24 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
WO2008022060A2 (en) 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
US8198266B2 (en) 2006-10-31 2012-06-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of an EGFR antagonist for the treatment of glomerolonephritis
WO2009004650A1 (en) 2007-06-29 2009-01-08 Torrent Pharmaceuticals Ltd. Novel substituted piperidones as hsp inducers
WO2010019210A2 (en) 2008-08-11 2010-02-18 President And Fellows Of Harvard College Halofuginone analogs for inhibition of trna synthetases and uses thereof
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
EP2894165B1 (en) 2008-11-10 2023-01-04 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
SG172338A1 (en) 2008-12-22 2011-07-28 Chemocentryx Inc C5ar antagonists
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
US20120252792A1 (en) 2009-09-17 2012-10-04 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
US9126939B2 (en) * 2010-06-24 2015-09-08 Pingchen Fan C5AR antagonists
BR112014031375A2 (pt) 2012-06-20 2017-06-27 Novartis Ag moduladores da série de reação complementar e usos dos mesmos
CN105392803B (zh) 2013-05-08 2019-12-06 诺和诺德股份有限公司 C5aR拮抗剂的用途
MA52308A (fr) * 2014-09-29 2021-02-24 Chemocentryx Inc Procédés et intermédiaires pour la préparation d'antagonistes c5ar
MX2022006069A (es) 2016-01-14 2023-01-12 Chemocentryx Inc Metodo para tratar glomerulopatia c3.
CA3019137A1 (en) 2016-04-04 2017-10-12 Chemocentryx, Inc. Soluble c5ar antagonists
CN116635075A (zh) 2020-12-21 2023-08-22 坎莫森特里克斯公司 使用c5a抑制剂治疗c3肾小球病

Also Published As

Publication number Publication date
IL251061B (en) 2019-09-26
CN106999481A (zh) 2017-08-01
ES2802428T3 (es) 2021-01-19
MX368492B (es) 2019-10-04
MX2019011911A (es) 2019-11-25
SG11201702185UA (en) 2017-04-27
DK3200791T3 (da) 2020-05-25
ES2926828T3 (es) 2022-10-28
US11845729B2 (en) 2023-12-19
RU2017114960A (ru) 2018-11-07
NZ730123A (en) 2023-05-26
EP3682879B1 (en) 2022-08-03
EP3200791A1 (en) 2017-08-09
US10532982B2 (en) 2020-01-14
CN113121415A (zh) 2021-07-16
US20190276402A1 (en) 2019-09-12
AU2021204209B2 (en) 2022-10-06
US10266492B2 (en) 2019-04-23
US9745268B2 (en) 2017-08-29
EP3200791A4 (en) 2018-06-13
AU2015324111A1 (en) 2017-04-06
MX2017003789A (es) 2017-08-02
EP3682879A1 (en) 2020-07-22
EP3200791B1 (en) 2020-04-22
US20180072668A1 (en) 2018-03-15
US20200354320A1 (en) 2020-11-12
BR112017006232B1 (pt) 2022-10-11
CN106999481B (zh) 2021-04-16
JP6898229B6 (ja) 2021-07-28
NZ767823A (en) 2023-05-26
US20230008966A1 (en) 2023-01-12
PL3200791T3 (pl) 2020-08-10
WO2016053890A1 (en) 2016-04-07
RU2712233C2 (ru) 2020-01-27
KR20230149873A (ko) 2023-10-27
RU2017114960A3 (pt) 2019-04-10
JP6898229B2 (ja) 2021-07-07
PT3200791T (pt) 2020-05-06
IL251061A0 (en) 2017-04-30
US20160090357A1 (en) 2016-03-31
CA3220371A1 (en) 2016-04-07
CA2960733A1 (en) 2016-04-07
AU2021204209A1 (en) 2021-07-15
MA52308A (fr) 2021-02-24
KR102593431B1 (ko) 2023-10-23
AU2015324111B2 (en) 2021-04-01
JP2017529378A (ja) 2017-10-05
KR20170085492A (ko) 2017-07-24
CA2960733C (en) 2024-01-09

Similar Documents

Publication Publication Date Title
BR112017006232A2 (pt) processos e intermediários na preparação de antagonistas de c5ar
CL2016001871A1 (es) Anticuerpos humanos para pd-1
DK3556777T3 (da) Multispecifikke antistofkonstrukter
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
DK3143037T3 (da) Alpha4beta7-integrin-thioether-peptidantagonister
CL2016002638A1 (es) Nuevos inhibidores de la nitrificación
ES2897914T8 (es) Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
DK3132111T3 (da) Borehulsredskab
DK3109141T3 (da) Holder
DE112015003475A5 (de) Spannfutter
DE112015000004A5 (de) Werkzeugschieber
DE112015000008A5 (de) Werkzeugschieber
DK3778526T3 (da) Gipsplade
DE112015001583A5 (de) Haltevorrichtung
DK3416923T3 (da) Gipsplade
DK3310756T3 (da) Thromboxanreceptorantagonister
DK3212879T3 (da) Skæreværktøj
DK3559365T3 (da) Gipsplade
DK3359183T3 (da) Polyepitop-konstrukter til anvendelse i immunoterapy
ES1102633Y (es) Pantalon laboral
UA34341S (uk) Тримач різця
UA32428S (uk) Ножівка по гіпсокартону
TH1501007026B (th) เครื่องมือสำหรับความงาม
TH1601003823B (th) ระบบจัดการงาน

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/09/2015, OBSERVADAS AS CONDICOES LEGAIS